Bevacizumab improves the delivery and efficacy of paclitaxel
Authors:
- Keigo YorozuKYKeigo Yorozu
- Mitsue KurasawaMKMitsue Kurasawa
- Koh FurugakiKFKoh Furugaki
- Yoriko YamashitaYYYoriko Yamashita
- Kazushige MoriKMKazushige Mori
- Kaori Fujimoto-OuchiKFKaori Fujimoto-Ouchi
- 1 August 2010
- journal article
- case report
- Published by Wolters Kluwer Health in Anti-Cancer Drugs
- Vol. 21 (7) , 687-694
Abstract
It has been reported that bevacizumab in combination with paclitaxel significantly prolongs progression-free survival compared with paclitaxel alone in the initial treatment for metastatic breast cancer. To understand how bevacizumab enhances the efficacy of paclitaxel, we investigated the mechanism in a MX-1 human breast cancer xenograft model. The antitumor activity of bevacizumab at 5 mg/kg in combination with paclitaxel at 20 or 30 mg/kg was significantly higher than that of either agent alone. First, we measured the paclitaxel concentration in tumor to see whether bevacizumab enhances the activity by increasing the tumor concentration of paclitaxel. When given in combination with bevacizumab, the levels of paclitaxel in the tumor increased. Paclitaxel at 30 mg/kg with bevacizumab showed a similar tumor concentration as paclitaxel alone at either 60 or 100 mg/kg, with a similar degree of tumor growth inhibition. In contrast, no remarkable differences in paclitaxel concentration in the plasma or liver were observed between the paclitaxel monotherapy group and the paclitaxel plus bevacizumab group. An increase in paclitaxel concentration by bevacizumab was also found in another model, A549. In the same MX-1 model, vascular permeability in the tumor was significantly decreased by treatment with bevacizumab. There was no difference in microvessel density between the bevacizumab alone group and the combination group. Results suggest that the synergistic antitumor activity of paclitaxel and bevacizumab in combination may be a result of the increase in paclitaxel concentration in tumor resulting from the downregulation of vascular permeability when co-administered with bevacizumab.Keywords
This publication has 16 references indexed in Scilit:
- Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast CancerNew England Journal of Medicine, 2007
- Bevacizumab-Induced Transient Remodeling of the Vasculature in Neuroblastoma Xenografts Results in Improved Delivery and Efficacy of Systemically Administered ChemotherapyClinical Cancer Research, 2007
- Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung CancerNew England Journal of Medicine, 2006
- Phosphatidylinostol 3-Kinase Mediates Angiogenesis and Vascular Permeability Associated with Ovarian CarcinomaClinical Cancer Research, 2005
- Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic TherapyScience, 2005
- Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitroAngiogenesis, 2004
- Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11British Journal of Cancer, 2003
- Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivoNature, 1993
- The Vascular Endothelial Growth Factor Proteins: Identification of Biologically Relevant Regions by Neutralizing Monoclonal AntibodiesGrowth Factors, 1992
- Mechanism of action of taxolTrends in Pharmacological Sciences, 1992